IP Library Patent Application 15826101
Patent Application
App. No. 15/826,101

THERAPEUTIC COMPOSITIONS CONTAINING HARMINE AND ISOVANILLIN COMPONENTS, AND METHODS OF USE THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/826,101
Abstract

Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.

Claims (8)

1 . A method of treating a human cancer patient comprising the step of administering to said patient an anti-cancer composition of matter comprising harmaline and a compound of the structure

where Q9 is a C3 aldehyde, and Q10 and Q11 are both H, the ratio of said harmaline to said compound being from about 0.5:1 to 15:1, said compound being present at a level of from about 25-95% by weight, and said harmaline being present at a level of from about 5-75% by weight, based upon the total weight of the composition taken as 100% by weight.

2 . The composition of claim 1 , said composition consisting essentially of harmaline and said compound having the structure set forth in claim 1 .

3 . The composition of claim 1 , wherein at least one of said harmaline and said compound having the structures set forth in claim 1 is in the form of an ester, metal complex, or pharmaceutically acceptable salt.

4 . A method of treating a human cancer patient comprising the step of administering to said patient an anti-cancer composition prepared by a method comprising the step of mixing together harmaline and a compound of the structure

where Q9 is a C3 aldehyde, and Q10 and Q11 are both H, the ratio of said harmaline to said compound being from about 0.5:1 to 15:1, said compound being present at a level of from about 25-95% by weight, and said harmaline being present at a level of from about 5-75% by weight, based upon the total weight of the composition taken as 100% by weight.

5 . The method of claim 4 , said preparative method further including the step of mixing said harmaline and said compound as set forth in the structure of claim 4 in ethanol, and sonicating the mixture.

6 . The method of claim 4 , wherein, in said preparative method, at least one of said harmaline and said compound having the structures set forth in claim 4 is in the form of an ester, metal complex, or pharmaceutically acceptable salt.

Assignments (2)
MERGER Recorded Aug 30, 2018
From: IONS PHARMACEUTICAL S.A R.L.
To: ANKH LIFE SCIENCES LIMITED
Reel/Frame 046760/0741 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2017
From: ZAID, GENE H.; BURGOYNE, THOMAS W.; GENZADA PHARMACEUTICALS LLC
To: IONS PHARMACEUTICAL S.À R.L.
Reel/Frame 044252/0401 →